Ex vivo wound model on porcine skin for the evaluation of the antibiofilm activity of polyhexamethylene biguanide and ciprofloxacin.

This study aimed to standardize the use of an ex vivo wound model for the evaluation of compounds with antibiofilm activity. The in vitro susceptibility of Staphylococcus aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853 to ciprofloxacin and polyhexamethylene biguanide (PHMB) was evaluated in planktonic and biofilm growth. The effects of ciprofloxacin and PHMB on biofilms grown on porcine skin explants were evaluated by CFU-counting and confocal microscopy. MICs against S. aureus and P. aeruginosa were, respectively, 0.5 and 0.25 µg ml⁻1 for ciprofloxacin, and 0.78 and 6.25 µg ml⁻1 for PHMB. MBECs against S. aureus and P. aeruginosa were, respectively, 2 and 8 µg ml⁻1 for ciprofloxacin, and 12.5 and >25µg ml⁻1 for PHMB. Ciprofloxacin reduced (P<0.05) log CFU-counts of the biofilms grown ex vivo by 3 and 0.96 for S. aureus and P. aeruginosa, respectively, at MBEC, and by 0.58 and 8.12 against S. aureus and P. aeruginosa, respectively, at 2xMBEC. PHMB (100 µg/mL) reduced (P<0.05) log CFU-counts by 0.52 for S. aureus and 0.68 log for P. aeruginosa, leading to an overall decrease (P<0.05) in biofilm biomass. The proposed methodology to evaluate the susceptibility of biofilms grown ex vivo led to reproducible and reliable results.